Details for New Drug Application (NDA): 202049
✉ Email this page to a colleague
The generic ingredient in BRONCHITOL is mannitol. There are eighteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the mannitol profile page.
Summary for 202049
Tradename: | BRONCHITOL |
Applicant: | Pharmaxis Europe |
Ingredient: | mannitol |
Patents: | 0 |
Pharmacology for NDA: 202049
Mechanism of Action | Osmotic Activity |
Physiological Effect | Increased Diuresis |
Medical Subject Heading (MeSH) Categories for 202049
Suppliers and Packaging for NDA: 202049
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
BRONCHITOL | mannitol | POWDER;INHALATION | 202049 | NDA | Chiesi USA, Inc. | 10122-212 | 10122-212-02 | 1 BLISTER PACK in 1 CARTON (10122-212-02) / 10 CAPSULE in 1 BLISTER PACK (10122-212-01) |
BRONCHITOL | mannitol | POWDER;INHALATION | 202049 | NDA | Chiesi USA, Inc. | 10122-212 | 10122-212-04 | 1 BLISTER PACK in 1 CARTON (10122-212-04) / 10 CAPSULE in 1 BLISTER PACK (10122-212-01) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INHALATION | Strength | 40MG | ||||
Approval Date: | Oct 30, 2020 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Oct 30, 2027 | ||||||||
Regulatory Exclusivity Use: | ADD-ON MAINTENANCE THERAPY TO IMPROVE PULMONARY FUNCTION IN ADULT PATIENTS 18 YEARS OF AGE AND OLDER WITH CYSTIC FIBROSIS AND WHO HAVE PASSED THE BRONCHITOL TOLERANCE TEST |
Complete Access Available with Subscription